<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="130479">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01403402</url>
  </required_header>
  <id_info>
    <org_study_id>CMDPROS1</org_study_id>
    <nct_id>NCT01403402</nct_id>
  </id_info>
  <brief_title>Congenital Muscle Disease Study of Patient and Family Reported Medical Information</brief_title>
  <acronym>CMDPROS</acronym>
  <official_title>Congenital Muscle Disease Patient and Proxy Reported Outcome Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cure CMD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cure CMD</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Congenital Muscle Disease Patient and Proxy Reported Outcome Study (CMDPROS) is a
      longitudinal 10 year study to identify and trend care parameters, adverse events in the
      congenital muscle diseases using the Congenital Muscle Disease International Registry
      (CMDIR). The CMDIR registers individuals with congenital muscular dystrophy, congenital
      myopathy and extends to the limb girdle and late onset spectrum for both disease groups. The
      CMDIR was created to identify the global congenital muscle disease population for the
      purpose of raising awareness, standards of care, clinical trials and in the future a
      treatment or cure. The registry includes demographic, disease specific and diagnostic
      questions. Key care parameters are surveyed longitudinally by proxy and/or patient report,
      confirmed by medical records. Genetic reports are curated by a board certified genetic
      counselor with support provided to families to pursue molecular confirmation through
      referrals to national centers of excellence.

      Study hypothesis:

        1. To use patient and proxy reported survey answers and medical reports to build a
           longitudinal care and outcomes database across the congenital muscle diseases.

        2. To generate congenital muscle disease subtype specific adverse event rates and
           correlate with key care parameters.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Congenital Muscle Disease Patient and Proxy Reported Outcome Study (CMDPROS) is a
      longitudinal 10 year observational study to identify care and trend key care parameters and
      adverse events in the congenital muscle diseases using the Congenital Muscle Disease
      International Registry (CMDIR). The CMDIR registers individuals with and without genetic
      confirmation who have been given a clinical diagnosis of congenital muscular dystrophy
      through limb girdle spectrum, and congenital myopathy through late onset spectrum. The CMDIR
      is currently translated into 5 languages: French, German, Spanish, English and Portuguese
      with plans to add Chinese, Italian, Danish and Japanese.

      Identifying care parameters and adverse events in the rare genetic neuromuscular diseases
      can be difficult. Care is fragmented, genetic confirmation may not be prioritized by the
      medical community or covered by medical insurance and patients are scattered globally with
      potential challenges aggregating data across centers. Natural history studies are currently
      being launched. However, potential biases to participation include recruitment of the less
      severely affected patients given difficulty traveling secondary to a medically fragile
      condition. There is currently no treatment for these conditions; though optimizing and
      standardizing care and care delivery can promote significant gains in quality of life and
      survival. Identifying disease specific care parameters and correlating those parameters with
      adverse event rates will not only contribute to the development of evidence based guidelines
      but inform clinically meaningful outcomes for future clinical trials.

      Study hypothesis:

        1. To use patient and proxy reported survey answers and medical reports to build a
           longitudinal care and outcomes database across the congenital muscle diseases.

        2. To generate congenital muscle disease subtype specific adverse event rates and
           correlate with key care parameters.

      Primary outcome is survival measured from date of birth to date of death. Primary outcome
      will be analyzed by congenital muscle disease subtype and maximal ambulatory status
      achieved.

      Secondary outcomes include disease specific adverse event rates including rates of
      hospitalization, rates of antibiotic use, rates of pulmonary infections, pneumothorax,
      atelectasis, aspiration and adverse complaints including bloating, constipation, chest pain,
      dyspnea assessed by a validated breathing assessment, vomiting and nausea and difficulty
      eating. Patient and proxy hospitalization, pneumothorax and atelectasis reports will be
      confirmed by obtaining hospital discharge summaries. Additional secondary outcomes include
      ejection fraction (relevance subtype specific), forced vital capacity in liters, weight,
      Rapid Eye Movement (REM) sleep apnea hypopnea index and mean oxygen saturation during REM
      and total sleep study, age, gender, type of treatment center location (national referral
      center, tertiary care hospital, community hospital), gastrostomy tube, total number of
      fractures and Tscore/Zscore of hip and spine on DEXA scans.

      Preliminary studies may focus on specific congenital muscle disease subtypes and use
      retrospective data collection through registry, survey monkey and telephone interviews to
      assess adverse event rates over last month and last year to limit recall bias. Prospective
      enrollment of same study participants over 12 months will assess monthly rates of adverse
      events and complaints. A preliminary study, CMD PROADE (Patient and Proxy Reported ADverse
      Event Rates) is planned in 2 congenital muscular dystrophy subtypes: Collagen 6 Myopathy and
      LAMA 2 Related CMD.

      De-identified data from CMDIR will be made available for IRB approved natural history
      studies in the congenital muscle diseases.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Anticipated">September 2019</completion_date>
  <primary_completion_date type="Anticipated">September 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Congenital Muscle Disease Patient and Proxy Reported Outcomes</measure>
    <time_frame>10 years</time_frame>
    <description>Correlation between genetic and biopsy findings and their relation to phenotypic and adverse event data.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Muscular Dystrophy</condition>
  <condition>Congenital Muscular Dystrophy</condition>
  <condition>Fukutin-related Protein Gene</condition>
  <condition>Limb Girdle</condition>
  <condition>FKRP Gene</condition>
  <condition>Childhood Onset LGMD</condition>
  <condition>Adult Onset LGMD</condition>
  <condition>POMT1</condition>
  <condition>POMT2</condition>
  <condition>POMGnT1</condition>
  <condition>LARGE</condition>
  <condition>Alpha Dystroglycan</condition>
  <condition>Dystroglycanopathy</condition>
  <condition>Centronuclear</condition>
  <condition>Multiminicore</condition>
  <condition>Multicore</condition>
  <condition>Minicore</condition>
  <condition>Congenital Fiber Type Disproportion</condition>
  <condition>Myotubular</condition>
  <condition>Nemaline</condition>
  <condition>Congenital Myopathy</condition>
  <condition>Neuromuscular</condition>
  <condition>Rigid Spine</condition>
  <condition>Phenotype-Genotype Correlation</condition>
  <condition>Cough Assisted Device</condition>
  <condition>Neuromuscular Disease</condition>
  <condition>Respiratory Exacerbation</condition>
  <condition>Invasive Ventilation</condition>
  <condition>Chest Physiotherapy</condition>
  <condition>Congenital Myopathies</condition>
  <condition>Genetic Mutations</condition>
  <condition>Hypertrophic Cardiomyopathy</condition>
  <condition>Wheelchair Use</condition>
  <condition>Cataract</condition>
  <condition>Opthalmoplegia</condition>
  <condition>Ullrich Congenital Muscular Dystrophy</condition>
  <condition>Intermediate Collagen VI Myopathy</condition>
  <condition>Laminin Alpha 2 Related Congenital Muscular Dystrophy</condition>
  <condition>MDC1A</condition>
  <condition>Merosin Deficient Congenital Muscular Dystrophy</condition>
  <condition>Congenital Muscular Dystrophy Undiagnosed</condition>
  <condition>Congenital Muscular Dystrophy Merosin Positive</condition>
  <condition>Walker Warburg Syndrome</condition>
  <condition>Muscle Eye Brain Disease</condition>
  <condition>Fukuyama</condition>
  <condition>Integrin Alpha 7 Deficiency</condition>
  <condition>Integrin Alpha 9 Deficiency</condition>
  <condition>Laminopathy</condition>
  <condition>Lamin AC</condition>
  <condition>SEPN1 Related Myopathies</condition>
  <condition>Bethlem Myopathy</condition>
  <condition>Dystroglycanopathies</condition>
  <condition>LGMD2K</condition>
  <condition>LGMD2I</condition>
  <condition>LGMD2L</condition>
  <condition>LGMD2N</condition>
  <condition>Actin Aggregation Myopathy</condition>
  <condition>Cap Disease</condition>
  <condition>Central Core Disease</condition>
  <condition>Centronuclear Myopathy</condition>
  <condition>Core Rod Myopathy</condition>
  <condition>Hyaline Body Myopathy</condition>
  <condition>Multiminicore Myopathy</condition>
  <condition>Myotubular Myopathy</condition>
  <condition>Nemaline Myopathy</condition>
  <condition>Tubular Aggregate Myopathy</condition>
  <condition>Zebra Body Disease Myopathy</condition>
  <condition>Congenital Myopathy Other</condition>
  <condition>Reducing Body Myopathy</condition>
  <condition>Sarcotubular Myopathy</condition>
  <condition>Spheroid Body Myopathy</condition>
  <arm_group>
    <arm_group_label>congenital muscle disease</arm_group_label>
    <description>The congenital muscle diseases include both congenital muscular dystrophy and congenital myopathy across the limb girdle and late onset spectrum. For data collection and analysis, subtype specific reports will be generated. True incidence of congenital muscular dystrophy and congenital myopathy is unknown. Current incidence and prevalence numbers for the congenital muscular dystrophies are based on a 1996 Italian population survey prior to molecular diagnostic testing with incidence (1/21,500) and prevalence (1/125,000).</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Participants in CMDPROS will be selected from the CMD International Registry (CMDIR) and
        currently include patients and families with congenital muscle disease from 25 countries.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Congenital Muscular Dystrophy subtypes included:

        Ullrich CMD (early onset) and Intermediate Collagen VI myopathy Laminin Alpha 2 Related
        CMD (MDC1A/Merosin def CMD) Dystroglycanopathy (WWS, MEB, Fukuyama) Integrin alpha 7
        deficiency Integrin alpha 9 deficiency Laminopathy (Lamin A/C) SEPN 1 related myopathies
        (Rigid Spine muscular dystrophy) CMD, undiagnosed (including merosin positive)

        Limb Girdle Muscular Dsytrophy subtypes included:

        Bethlem myopathy Dystroglycanopathies (LGMD2K, LGMD2I, LGMD2L, LGMD2N) Telethoninopathy

        Congenital Myopathy subtypes included by muscle biopsy pathology and defined subtypes:

        Actin aggregation myopathy Cap disease Central core disease Centronuclear myopathy
        Congenital fiber type disporportion Core rod myopathy Hyaline body myopathy Multiminicore
        myopathy Myotubular myopathy Nemaline myopathy Tubular aggregate myopathy Zebra body
        disease myopathy Congenital myopathy, other

        Later onset subtypes of myopathy included:

        Reducing body myopathy Sarcotubular myopathy Spheroid body myopathy

        Exclusion Criteria: Duchenne muscular dystrophy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anne Rutkowski, MD</last_name>
    <role>Study Chair</role>
    <affiliation>CureCMD, CMDIR</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rachel Alvarez, BA</last_name>
    <phone>3232502399</phone>
    <email>rachel.alvarez@cmdir.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Congenital Muscle Disease International Registry (www.cmdir.org)</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rachel Alvarez</last_name>
      <email>counselor@cmdir.org</email>
    </contact>
    <investigator>
      <last_name>Anne Rutkowski, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Bönnemann CG, Rutkowski A, Mercuri E, Muntoni F; CMD Outcomes Consortium.. 173rd ENMC International Workshop: congenital muscular dystrophy outcome measures 5-7 March 2010, Naarden, The Netherlands. Neuromuscul Disord. 2011 Jul;21(7):513-22. doi: 10.1016/j.nmd.2011.04.004. Epub 2011 Jun 8.</citation>
    <PMID>21641800</PMID>
  </reference>
  <reference>
    <citation>Wang CH, Bonnemann CG, Rutkowski A, Sejersen T, Bellini J, Battista V, Florence JM, Schara U, Schuler PM, Wahbi K, Aloysius A, Bash RO, Béroud C, Bertini E, Bushby K, Cohn RD, Connolly AM, Deconinck N, Desguerre I, Eagle M, Estournet-Mathiaud B, Ferreiro A, Fujak A, Goemans N, Iannaccone ST, Jouinot P, Main M, Melacini P, Mueller-Felber W, Muntoni F, Nelson LL, Rahbek J, Quijano-Roy S, Sewry C, Storhaug K, Simonds A, Tseng B, Vajsar J, Vianello A, Zeller R; International Standard of Care Committee for Congenital Muscular Dystrophy.. Consensus statement on standard of care for congenital muscular dystrophies. J Child Neurol. 2010 Dec;25(12):1559-81. doi: 10.1177/0883073810381924. Epub 2010 Nov 15. Review.</citation>
    <PMID>21078917</PMID>
  </reference>
  <reference>
    <citation>Sparks SE, Quijano-Roy S, Harper A, Rutkowski A, Gordon E, Hoffman EP, Pegoraro E. Congenital Muscular Dystrophy Overview. 2001 Jan 22 [updated 2012 Aug 23]. In: Pagon RA, Adam MP, Ardinger HH, Wallace SE, Amemiya A, Bean LJH, Bird TD, Ledbetter N, Mefford HC, Smith RJH, Stephens K, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2017. Available from http://www.ncbi.nlm.nih.gov/books/NBK1291/</citation>
    <PMID>20301468</PMID>
  </reference>
  <reference>
    <citation>Geranmayeh F, Clement E, Feng LH, Sewry C, Pagan J, Mein R, Abbs S, Brueton L, Childs AM, Jungbluth H, De Goede CG, Lynch B, Lin JP, Chow G, Sousa Cd, O'Mahony O, Majumdar A, Straub V, Bushby K, Muntoni F. Genotype-phenotype correlation in a large population of muscular dystrophy patients with LAMA2 mutations. Neuromuscul Disord. 2010 Apr;20(4):241-50. doi: 10.1016/j.nmd.2010.02.001. Epub 2010 Mar 6.</citation>
    <PMID>20207543</PMID>
  </reference>
  <reference>
    <citation>Sewry CA, Jimenez-Mallebrera C, Muntoni F. Congenital myopathies. Curr Opin Neurol. 2008 Oct;21(5):569-75. doi: 10.1097/WCO.0b013e32830f93c7. Review.</citation>
    <PMID>18769251</PMID>
  </reference>
  <reference>
    <citation>Klein A, Clement E, Mercuri E, Muntoni F. Differential diagnosis of congenital muscular dystrophies. Eur J Paediatr Neurol. 2008 Sep;12(5):371-7. doi: 10.1016/j.ejpn.2007.10.002. Epub 2007 Dec 3.</citation>
    <PMID>18588847</PMID>
  </reference>
  <reference>
    <citation>Godfrey C, Clement E, Mein R, Brockington M, Smith J, Talim B, Straub V, Robb S, Quinlivan R, Feng L, Jimenez-Mallebrera C, Mercuri E, Manzur AY, Kinali M, Torelli S, Brown SC, Sewry CA, Bushby K, Topaloglu H, North K, Abbs S, Muntoni F. Refining genotype phenotype correlations in muscular dystrophies with defective glycosylation of dystroglycan. Brain. 2007 Oct;130(Pt 10):2725-35. Epub 2007 Sep 18.</citation>
    <PMID>17878207</PMID>
  </reference>
  <reference>
    <citation>Ramelli GP, Aloysius A, King C, Davis T, Muntoni F. Gastrostomy placement in paediatric patients with neuromuscular disorders: indications and outcome. Dev Med Child Neurol. 2007 May;49(5):367-71.</citation>
    <PMID>17489811</PMID>
  </reference>
  <reference>
    <citation>Mellies U, Dohna-Schwake C, Voit T. Respiratory function assessment and intervention in neuromuscular disorders. Curr Opin Neurol. 2005 Oct;18(5):543-7. Review.</citation>
    <PMID>16155437</PMID>
  </reference>
  <reference>
    <citation>Takaso M, Nakazawa T, Imura T, Okada T, Ueno M, Saito W, Takahashi K, Yamazaki M, Ohtori S. Surgical correction of spinal deformity in patients with congenital muscular dystrophy. J Orthop Sci. 2010 Jul;15(4):493-501. doi: 10.1007/s00776-010-1486-9. Epub 2010 Aug 19.</citation>
    <PMID>20721717</PMID>
  </reference>
  <reference>
    <citation>Schara U, Kress W, Bönnemann CG, Breitbach-Faller N, Korenke CG, Schreiber G, Stoetter M, Ferreiro A, von der Hagen M. The phenotype and long-term follow-up in 11 patients with juvenile selenoprotein N1-related myopathy. Eur J Paediatr Neurol. 2008 May;12(3):224-30. Epub 2007 Oct 22.</citation>
    <PMID>17951086</PMID>
  </reference>
  <reference>
    <citation>Nadeau A, Kinali M, Main M, Jimenez-Mallebrera C, Aloysius A, Clement E, North B, Manzur AY, Robb SA, Mercuri E, Muntoni F. Natural history of Ullrich congenital muscular dystrophy. Neurology. 2009 Jul 7;73(1):25-31. doi: 10.1212/WNL.0b013e3181aae851.</citation>
    <PMID>19564581</PMID>
  </reference>
  <reference>
    <citation>van den Engel-Hoek L, Erasmus CE, de Swart BJ, Sie LT, de Groot IJ. Neonatal swallowing assessment and practical recommendations for oral feeding in a girl with a severe congenital myopathy. J Child Neurol. 2011 Aug;26(8):1041-4. doi: 10.1177/0883073811402071. Epub 2011 May 3.</citation>
    <PMID>21540369</PMID>
  </reference>
  <reference>
    <citation>Saito Y, Komaki H, Hattori A, Takeuchi F, Sasaki M, Kawabata K, Mitsuhashi S, Tominaga K, Hayashi YK, Nowak KJ, Laing NG, Nonaka I, Nishino I. Extramuscular manifestations in children with severe congenital myopathy due to ACTA1 gene mutations. Neuromuscul Disord. 2011 Jul;21(7):489-93. doi: 10.1016/j.nmd.2011.03.004. Epub 2011 Apr 21.</citation>
    <PMID>21514153</PMID>
  </reference>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>January 30, 2017</lastchanged_date>
  <firstreceived_date>July 26, 2011</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Eye Diseases, Hereditary</keyword>
  <keyword>Retinal Dystrophies</keyword>
  <keyword>Retinal Degeneration</keyword>
  <keyword>Genetic Diseases, X-Linked</keyword>
  <keyword>Genetic Diseases, Inborn</keyword>
  <keyword>Pathologic Processes</keyword>
  <keyword>Respiration Disorders</keyword>
  <keyword>Eye Diseases</keyword>
  <keyword>Cardiomyopathy, Hypertrophic</keyword>
  <keyword>Hypertrophy</keyword>
  <keyword>Cardiomyopathies</keyword>
  <keyword>Heart Diseases</keyword>
  <keyword>Central Nervous System Diseases</keyword>
  <keyword>Nervous System Diseases</keyword>
  <keyword>Muscular Diseases</keyword>
  <keyword>Muscular Dystrophies</keyword>
  <keyword>Myopathies, Structural, Congenital</keyword>
  <keyword>Muscular Disorders, Atrophic</keyword>
  <keyword>Neuromuscular Diseases</keyword>
  <keyword>Myopathies, Nemaline</keyword>
  <keyword>Musculoskeletal Diseases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cataract</mesh_term>
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Muscular Dystrophies</mesh_term>
    <mesh_term>Hypertrophy</mesh_term>
    <mesh_term>Muscular Diseases</mesh_term>
    <mesh_term>Cardiomyopathy, Hypertrophic</mesh_term>
    <mesh_term>Neuromuscular Diseases</mesh_term>
    <mesh_term>Brain Diseases</mesh_term>
    <mesh_term>Myopathies, Structural, Congenital</mesh_term>
    <mesh_term>Myopathies, Nemaline</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Myopathy, Central Core</mesh_term>
    <mesh_term>Walker-Warburg Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
